An Act amending the act of November 3, 2022 (P.L.2135, No.150), known as the Childhood Blood Lead Test Act, further providing for title of act, for legislative purpose, for definitions, for lead poisoning prevention, assessment and testing, for duties of department and for blood lead assessment and testing coverage.

HB 916 amends Pennsylvania's Childhood Blood Lead Test Act to update requirements for lead screening and testing of children under 72 months and pregnant women. It defines key terms like "blood lead level" (measured in micrograms per deciliter) and establishes that lead poisoning is confirmed at 20 µg/dL or two tests showing 15 µg/dL over 90 days. The bill repeals older testing protocols and mandates healthcare providers to test children by age 2, follow up on elevated results within 12 weeks, and assess lead exposure risks for pregnant women. It clarifies that "screening" identifies risk in asymptomatic patients, while "diagnostic" testing confirms poisoning. The changes directly affect pediatric and prenatal care providers, insurers, and families in Pennsylvania.